Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China
The combination of benmelstobart and anlotinib with chemotherapy is not a cost-effective first-line treatment option for ES-SCLC in either China or the US.
Authors
- Ming Ouyang (ORCID: https://orcid.org/0000-0001-5890-377X)
- Lingyue Huang
- Haiqing Zhao (ORCID: https://orcid.org/0000-0003-4275-9843)
- Tingting Zhou (ORCID: https://orcid.org/0000-0002-9967-0068)
- W.J. Lang (ORCID: https://orcid.org/0009-0007-3583-9518)
- Jiangbo Wang (ORCID: https://orcid.org/0000-0002-1117-7771)
Institutions
- Nanxi Mountain Hospital (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1371/journal.pone.0331338
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00